These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15744218)

  • 1. Ziprasidone as an augmenting agent in the treatment of anxiety-spectrum disorders.
    Crane DL
    CNS Spectr; 2005 Mar; 10(3):176-9. PubMed ID: 15744218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.
    Papakostas GI; Petersen TJ; Nierenberg AA; Murakami JL; Alpert JE; Rosenbaum JF; Fava M
    J Clin Psychiatry; 2004 Feb; 65(2):217-21. PubMed ID: 15003076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mania from dose-related ziprasidone augmentation of an SSRI.
    Privitera MR; Maharaj K
    J Clin Psychiatry; 2003 Nov; 64(11):1393-4. PubMed ID: 14658958
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder.
    Suppes T; McElroy SL; Sheehan DV; Hidalgo RB; Cosgrove VE; Gwizdowski IS; Feldman NS
    J Clin Psychiatry; 2014 Jan; 75(1):77-84. PubMed ID: 24345758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study.
    Mischoulon D; Shelton RC; Baer L; Bobo WV; Curren L; Fava M; Papakostas GI
    J Clin Psychiatry; 2017 Apr; 78(4):449-455. PubMed ID: 27835715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder.
    Sarkar R; Klein J; Krüger S
    Psychopharmacology (Berl); 2008 May; 197(4):687-8. PubMed ID: 18264798
    [No Abstract]   [Full Text] [Related]  

  • 7. Ziprasidone-associated mania in a case of obssessive-compulsive disorder.
    Wickham R; Varma A
    CNS Spectr; 2007 Aug; 12(8):578-9. PubMed ID: 17924512
    [No Abstract]   [Full Text] [Related]  

  • 8. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder.
    Hoge EA; Worthington JJ; Kaufman RE; Delong HR; Pollack MH; Simon NM
    CNS Spectr; 2008 Jun; 13(6):522-7. PubMed ID: 18567977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ziprasidone Augmentation of SSRI Antidepressants in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Pilot Study of Augmentation Therapy.
    Hamner MB; Hernandez-Tejada MA; Zuschlag ZD; Agbor-Tabi D; Huber M; Wang Z
    J Clin Psychopharmacol; 2019; 39(2):153-157. PubMed ID: 30640209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quetiapine augmentation of selective serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a six-month follow-up case series.
    Dell'Osso B; Mundo E; Altamura AC
    CNS Spectr; 2006 Nov; 11(11):879-83; quiz 885. PubMed ID: 17075559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder.
    Storch EA; Lehmkuhl H; Geffken GR; Touchton A; Murphy TK
    Depress Anxiety; 2008; 25(2):172-4. PubMed ID: 17340610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
    Ak M; Bulut SD; Bozkurt A; Ozsahin A
    Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary add-on of ziprasidone in sertraline treatment of posttraumatic stress disorder: lessons from a stopped trial?
    Kellner M; Muhtz C; Wiedemann K
    J Clin Psychopharmacol; 2010 Aug; 30(4):471-3. PubMed ID: 20631571
    [No Abstract]   [Full Text] [Related]  

  • 14. Clozapine and ziprasidone: a useful combination in patients with treatment-resistant schizophrenia.
    Ziegenbein M; Calliess IT
    J Neuropsychiatry Clin Neurosci; 2006; 18(2):246-7. PubMed ID: 16720806
    [No Abstract]   [Full Text] [Related]  

  • 15. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine augmentation in panic disorder: a case report.
    Chao I
    Pharmacopsychiatry; 2004 Sep; 37(5):239-40. PubMed ID: 15470803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recent trends in pharmacotherapy for anxiety disorders].
    Tajima O
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Jun; 24(3):133-6. PubMed ID: 15291242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary retention with sertraline, haloperidol, and clonazepam combination.
    Benazzi F
    Can J Psychiatry; 1998 Dec; 43(10):1051-2. PubMed ID: 9868574
    [No Abstract]   [Full Text] [Related]  

  • 19. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
    Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
    J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder.
    Snyderman SH; Rynn MA; Rickels K
    J Clin Psychopharmacol; 2005 Oct; 25(5):497-9. PubMed ID: 16160630
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.